Daily Anesthesiology Research Analysis
Analyzed 81 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology studies stand out: a multicenter randomized trial shows a reinforcement learning-based automated anesthesia system achieves non-inferior safety and faster induction for endoscopy; a double-blind RCT demonstrates 4 mg ondansetron halves spinal-induced hypotension in preeclamptic cesarean deliveries; and a large prospective cohort identifies intraoperative renal pulsatility index as an early marker of AKI after cardiac surgery.
Research Themes
- AI-enabled automated anesthesia and perioperative efficiency
- Hemodynamic prophylaxis in high-risk obstetric anesthesia
- Point-of-care Doppler ultrasound biomarkers for perioperative AKI
Selected Articles
1. Reinforcement learning based automated anesthesia system for gastrointestinal endoscopy with a multicenter randomized trial.
In a multicenter RCT of 418 adults undergoing GI endoscopy, an RL-based automated system for ciprofol delivery achieved non-inferior hypoxemia rates to clinician-managed anesthesia and significantly shortened induction time without increasing drug use or recovery time. More intraoperative movement occurred under the automated system, consistent with lighter anesthetic depth.
Impact: This is one of the first prospective multicenter RCTs validating RL-driven autonomous anesthesia, demonstrating safety parity and operational efficiency gains.
Clinical Implications: Automated sedation for endoscopy could standardize safety, reduce induction time, and alleviate staffing pressures, with attention to movement management (e.g., adjuncts or depth targets).
Key Findings
- Hypoxemia incidence was similar between automated and clinician groups (14.42% vs 14.29%; OR 1.01, 95% CI 0.59–1.75; P=0.968).
- Induction time was shorter with automation (median 1.55 vs 1.90 minutes; P<0.001).
- No increase in total drug dose or recovery time; intraoperative body movement was more frequent under automated control.
Methodological Strengths
- Prospective multicenter randomized controlled design with clinical registration (NCT06857344)
- Clear primary safety endpoint with predefined hypoxemia threshold and robust secondary outcomes
Limitations
- Restricted to ASA I–II adults and endoscopy with ciprofol; generalizability to higher-risk populations and other agents is unknown
- Increased intraoperative movement suggests need for optimization of depth targets or adjuncts
Future Directions: Evaluate RL control across higher-risk cohorts, different procedures and agents, integrate movement/depth mitigation strategies, and assess workflow and cost-effectiveness.
The increasing demand for gastrointestinal endoscopic procedures, coupled with a global shortage of anesthesiologists, underscores the need for intelligent automation in anesthesia care. Reinforcement learning (RL) offers a promising strategy for autonomous anesthesia control, yet prospective clinical validation remains limited. We developed an RL-based automated anesthesia system for gastrointestinal endoscopy (AAS-GE) for automated ciprofol delivery and conducted a prospective, multicenter, randomized controlled trial across four centers in China between January 8 and August 27, 2025. Adults aged 18-65 years with American Society of Anesthesiologists physical status I-II undergoing gastrointestinal endoscopy were randomized 1:1 to receive either AAS-GE-controlled anesthesia or clinician-managed manual anesthesia. The primary outcome was the incidence of hypoxemia, defined as oxygen saturation below 92%, with secondary outcomes assessing hypoxemia severity, induction time, drug use, recovery, and adverse events. A total of 509 participants were included in algorithm development, and 418 were enrolled for clinical validation. The incidence of hypoxemia was comparable between groups (14.42 vs. 14.29%; odds ratio 1.01, 95% CI 0.59-1.75; P = 0.968), with no significant differences in secondary safety outcomes. AAS-GE achieved a shorter induction time (median 1.55 vs. 1.90 min; P < 0.001) without increasing total drug dose or recovery time. However, intraoperative body movement was more frequent in the AAS-GE group, consistent with lighter anesthesia depth. These results demonstrate the non-inferior safety and efficacy of AAS-GE compared with clinician management, supporting its potential to improve efficiency and standardize sedation care. Clinical registration: ClinicalTrials.gov on Feb. 26, 2025 (NCT06857344).
2. The effect of intravenous ondansetron on maternal spinal-induced hypotension in preeclamptic patients undergoing caesarean delivery: A randomised, controlled clinical trial.
In a double-blind RCT of 120 preeclamptic parturients, 4 mg IV ondansetron given 10 minutes before spinal anesthesia reduced hypotension from 55% to 30% (RR 0.55) and lowered phenylephrine requirements without adverse neonatal effects.
Impact: Addresses a high-risk obstetric population where vasopressor prophylaxis is challenging; demonstrates a simple, low-dose 5-HT3 antagonist strategy to mitigate hypotension.
Clinical Implications: Consider 4 mg IV ondansetron pre-spinal in preeclamptic cesarean delivery to reduce hypotension and vasopressor use, with ongoing hemodynamic and fetal monitoring.
Key Findings
- Hypotension incidence reduced with ondansetron vs placebo (30% vs 55%; mean difference 25%, 95% CI 8.4–43.9%; P=0.0009).
- Relative risk of hypotension with ondansetron was 0.55 (95% CI 0.34–0.84).
- Phenylephrine requirement decreased; no adverse neonatal outcomes difference observed.
Methodological Strengths
- Prospective, double-blind, randomized controlled design
- Clear primary endpoint and clinically relevant secondary outcomes
Limitations
- Single-center study limits generalizability
- Only a single 4 mg dose tested; dose–response and optimal timing remain to be defined
Future Directions: Multicenter validation, dose-finding, interaction with vasopressor prophylaxis, and evaluation in varying severities of preeclampsia.
BACKGROUND: Prophylactic vasopressor infusions have been recommended for preventing spinal-induced hypotension during caesarean delivery in normotensive patients, but they should be used with caution in patients with preeclampsia due to concerns about exacerbating their haemodynamic instability. Ondansetron has been reported to effectively reduce the incidence of hypotension and decrease the need for vasopressors without causing significant adverse effects in both obstetric and nonobstetric patients undergoing spinal anaesthesia. Nevertheless, evidence regarding its use specifically in patients with preeclampsia remains limited. OBJECTIVE: This study aimed to evaluate the efficacy of ondansetron in preventing spinal anaesthesia-induced hypotension in preeclamptic patients undergoing caesarean delivery. DESIGN: A prospective, double-blinded, randomised clinical trial. SETTING: Single university hospital. PARTICIPANTS: One hundred and twenty preeclamptic patients were enrolled and allocated to Group O and Group C. INTERVENTIONS: Patients in Group O receive intravenous ondansetron (4 mg 2 ml-1) or in Group C receive 0.9% saline placebo (2 ml) 10 min before spinal injection. MAIN OUTCOME MEARSURES: The primary outcome of the study was the incidence of hypotension. Secondary outcomes included consumption of phenylephrine, the incidence of side effects, and neonatal outcomes. RESULTS: The incidence of spinal anaesthesia-induced hypotension was higher in Group C than in Group O (55 vs. 30%, mean difference: 25%, 95% CI, 8.4 to 43.9%; P = 0.0009). The relative risk of hypotension associated with or without intravenous ondansetron administration was 0.55 (95% CI, 0.34 to 0.84). CONCLUSION: The intravenous administration of 4 mg of ondansetron can effectively reduce the incidence of spinal anaesthesia-induced hypotension, and consequently decrease the requirement for phenylephrine in patients with preeclampsia undergoing caesarean delivery. TRIAL REGISTRATION: ChiCTR2400080284.
3. Renal pulsatility index assessment by intraoperative doppler ultrasound is associated with acute kidney injury after cardiac surgery: a prospective observational study.
In a 500-patient prospective cohort, immediate postoperative renal pulsatility index measured intraoperatively was independently associated with KDIGO-defined AKI (OR 3.72), with a suggested cutoff of 1.305. Earlier timepoints showed no significant differences.
Impact: Demonstrates a practical, point-of-care Doppler biomarker for early AKI risk stratification after cardiac surgery in a large prospective cohort.
Clinical Implications: Intraoperative/postoperative renal Doppler may help identify high-risk patients for renal-protective strategies, hemodynamic optimization, and closer monitoring.
Key Findings
- AKI occurred in 32.2% (161/500); moderate–severe in 46 patients.
- RPI at immediate post-surgery (T3) was higher in AKI vs non-AKI (1.44±0.34 vs 1.30±0.28; P=0.004).
- T3 RPI independently associated with AKI (OR 3.72, 95% CI 1.92–7.20); spline suggested cutoff 1.305.
Methodological Strengths
- Large prospective cohort with standardized intraoperative Doppler measurements at four timepoints
- Multivariable modeling and spline analysis to define risk association and threshold
Limitations
- Observational design cannot infer causality
- Single specialty setting; external validation of cutoff and integration into protocols needed
Future Directions: External validation, interventional trials targeting hemodynamics by RPI, and integration with multimodal AKI prediction tools.
BACKGROUND: Acute kidney injury (AKI) is a common complication among patients undergoing cardiac surgery. Perioperative ultrasound assessment of renal hemodynamic parameters has emerged as a potential tool for predicting postoperative AKI. This study aimed to investigate whether the renal pulsatility index (RPI) could serve as an early diagnostic marker for the development of AKI (Kidney Disease Improving Global Outcomes, KDIGO-defined) following cardiac surgery. METHODS: This prospective observational study enrolled 500 patients meeting the inclusion criteria. The RPI was measured at 4 time points: prior to anesthesia (T0), after anesthesia induction (T1), after the completion of cardiopulmonary bypass (T2), immediately after the surgery (T3). The primary endpoint was the incidence of AKI. Three logistic regression models were constructed to evaluate the association between RPI and AKI. The associations between RPI and moderate to severe AKI were analyzed and served as sensitivity analysis. RESULTS: A total of 161 patients (32.2%) developed AKI. Among them, 46 classified as moderate to severe AKI. Compared with patients without AKI, patients with AKI had a significantly higher RPI at T3 (1.30 ± 0.28 vs 1.44 ± 0.34, P = 0.004), while no significant differences were observed at the other time points. Multivariable analysis revealed that RPI at T3 was associated with postoperative AKI (OR = 3.72, 95% CI 1.92-7.20; P < 0.001). The restricted cubic splines revealed an RPI cutoff value of 1.305 at T3, above which the risk of AKI increased proportionally. CONCLUSION: An elevated RPI immediately after surgery was associated with increased risk of AKI after cardiac surgery.